Application of minimally invasive surgery-multidisciplinary team in advanced and recurrent gynecological cancers: 10-year exploration and practice

• Published in: Gynecology and minimally invasive therapy Vol. 12; no. 3; pp. 141 - 147
• Main Authors: Li, Caixia, Wang, Zhongjie, Yang, Weihong, Ai, Guihai, Cheng, Zhongping
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer India Pvt. Ltd 01-07-2023; Medknow Publications and Media Pvt. Ltd; Wolters Kluwer - Medknow; Wolters Kluwer Medknow Publications
• Subjects: advanced and recurrent gynecological cancers; Cancer; Care and treatment; Diseases; minimally invasive surgery; multidisciplinary team; Original; Relapse; Surgery; minimally invasive surgery; Advanced and recurrent gynecological cancers; multidisciplinary team
• ISSN: 2213-3070; 2213-3089
• DOI: 10.4103/gmit.gmit_64_22

Objectives: The treatment of advanced and recurrent gynecological cancers (ARGCs) remains more difficult evens. This assay aims to introduce the application of minimally invasive surgery-multidisciplinary team (MIS-MDT) as well as a comprehensive evaluation and treatment program of ARGC.
Materials and Methods: The diagnosis and treatment model of MDT collaboration has become a new model of clinical cancer treatment. In my country, it is in the start-up and trial stage. Our team began to explore surgical treatment of recurrent gynecological cancers in 2011 and has been committed to MDT treatment of ARGC for more than 3 years.
Results: So far, 61 patients have completed MDT treatment (28 of them were advanced gynecological cancer patients, 33 of them were recurrent gynecological cancer patients). Among them, MDT involved 43 times in gastrointestinal surgery, 21 times in urology, 5 times in the department of intractable abdominal diseases, and 5 times in other departments. After surgery, 58 patients (95%) restarted adjuvant therapy such as radiotherapy and chemotherapy. In addition, 32 patients (52.5%) underwent genetic and molecular testing, of which 14 patients (23%) accepted targeted and immunotherapy based on the testing results. After MIS-MDT treatment, the median progression-free survival of these patients was >30 months, respectively.
Conclusion: These patients have achieved good results after surgery of MDT. With continuous accumulation and summarization, we have systematically reviewed the diagnosis and treatment model of ARGC and guided clinical work as the model of Tongji Tenth Hospital (comprehensive evaluation and treatment).